MedTrace Logo

Non-inferiority Comparison of Efficacy and Safety of Penciclovir 10mg/g to Acyclovir 50mg/g in the Treatment of Recurrent Herpes Labialis

NCT01257074 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2013-03-04

No results posted yet for this study

Summary

Herpes labialis is the most common recurrent manifestation of herpes simplex. The purpose of this study is to check the non-inferiority efficacy and safety of penciclovir 10mg/g as treatment for Herpes Labialis in comparison to acyclovir 50mg/g.

Conditions

  • Herpes Labialis

Interventions

DRUG

Acyclovir 50mg/g

Cream, dose 5 times daily during 5 days

DRUG

Penciclovir 10mg/g

Cream, dose 5 times daily during 5 days

Sponsors & Collaborators

  • EMS

    lead INDUSTRY

Principal Investigators

  • Flavia Addor, MD · Medcin Instituto da Pele Ltda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2012-03-31
Completion
2012-10-31

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01257074 on ClinicalTrials.gov